Click Here to view the Journal of Managed Care Medicine
|
Announcing the NAMCP Medical Directors Lung Cancer Resource Center. Click here to visit the website.
|
Be sure to check out the study results of Verinata's Non-Invasive Prenatal Technology. Click here to view the press release.
|
Click here to check out the "Latest in Clinical Nutrition" DVD available for purchase now!
|
|
|
Stanford gene researchers see diabetes develop
San Francisco Chronicle
Share
   
Stanford researchers have unveiled the most detailed biological profile of a human being done so far: a peek at one man's genetic foundation, with snapshots of the millions of proteins and molecules in constant flux in his body. The research provides some proof that detailed genetic profiling could be used not just to predict an individual's chances of developing disease, but also to identify the smallest molecular changes that show when a person starts to become ill, personalized medicine experts said.
More
Genetic research could aid regenerative treatment
Medical Xpress
Share
Research from a Kansas State University professor may make it easier to recover after spinal cord injury or to study neurological disorders. He is researching genetic models for spinal cord injury or diseases such as Parkinson's disease. He is developing technology that can advance cellular therapy and regenerative medicine.
More
New drug a breakthrough for cystic fibrosis patients
The Seattle Times
Share
A new drug, Kalydeco, is the first medication that targets the genetic cause of cystic fibrosis, not just its symptoms. Although it is effective only for a small number of patients, the drug is hailed as an important breakthrough.
More
| Biotech/Diagnostics/Personalized Medicine |
Court throws out Prometheus drug patent
The Associated Press via Yahoo News
Share
The Supreme Court unanimously tossed out medical patent claims for Prometheus Laboratories for a test that could help doctors set drug doses for autoimmune diseases like Crohn's disease, a decision that could affect the burgeoning field of personalized medicine. The justices unanimously agreed the patents held by the company were invalid because they were based on the laws of nature, which are unpatentable.
More
Guidelines focus on newly diagnosed HIV patients
American Medical News
Share
Worried that too few people with HIV receive the care they need, infectious diseases experts have issued guidelines calling on physicians to ensure newly diagnosed patients start treatment and adhere to life-long drug regimens. The guidelines recommend after an initial visit for treatment programs, nurses or other staff members periodically call patients to ensure that they are properly taking their medications.
More
|
|
The world’s first remote glucose monitor
designed to provide protection
from overnight hypoglycemia.
MORE
|
|
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. We discover, develop, manufacture and market prescription medicines for cancer, cardiovascular, gastrointestinal and infection.
MORE
|
|
To fix a heart, doctors train girl's body to grow new part
The Wall Street Journal
Share
Scientists have long been captivated by the ability of animals such as salamanders and starfish to regrow body parts lost to injury. It was long assumed that developmental forces that create a human being in the womb are lost at birth. But recent advances in stem-cell research and tissue engineering suggest that regenerative forces can be reawakened with strategically implanted stem cells and other tissue.
More
True bionic limb remains far out of reach
Wired
Share
Prosthetics give their "best guess" in reacting to commands, one expert says. The problem bedevils all of the current research in prosthetics. Today's computer-controlled prosthetic arms can carry out only a few commands. A decade ago, researchers seemed on the cusp of creating a working interface between body and machine.
More
| Emerging Medical Technologies |
Building a better inhaler
The Atlantic
Share
 Asthma inhalers seem easy to use, but they require a good deal of precision during shaking, inhalation and pressing of the button. Cambridge Consultants has developed a practice inhaler, called T-Haler, that can correct improper usage. The device senses whether it received enough shaking, how much inhalation pressure was applied and whether the button was pressed at the right time to release the medication.
More
Researchers print live cells with inkjet printer
Bioscience Technology
Share
Researchers from Clemson University in South Carolina have found a way to create temporary holes in the membranes of live cells using a standard inkjet printer. The method will be published in the Journal of Visualized Experiments. Researchers have been using the method to print cells onto slides, but that they have only recently discovered that printing the cells causes the disruption in their membranes for a few hours.
More
Some 'uninsurables' face extra hurdle in covering preexisting ailments
The Washington Post
Share
The "uninsurables" — people with serious medical conditions who can't buy private health coverage — are supposed to have a safety net to rely on in the new preexisting condition insurance plans. These comprehensive plans, created by the federal healthcare law, take all comers who have been uninsured for at least six months.
More
CFO: Aetna ready for 'dual eligibles' despite commercial focus
The Wall Street Journal (subscription)
Share
Aetna believes it can ably serve health-challenged patients covered by both Medicare and Medicaid, even though the company doesn't have a major stake in those markets. Some of Aetna's big competitors have recently made deals with an eye on dual patients, and Aetna has faced questions about whether it has the right makeup for the market.
More
| FDA: New Treatments and Technology |
FDA to hold hearing on whether people can self-scan for scripts
KPCC
Share
 The Food and Drug Administration is preparing to hold hearings on whether consumers should be able to use new technologies to self-screen for some medications that now require a doctor's visit and a prescription. The drugs under consideration are limited to common treatments for asthma, diabetes, high blood pressure, high cholesterol and migraine headaches.
More
AstraZeneca gives up antidepressant
Reuters
Share
AstraZeneca has thrown in the towel on an experimental antidepressant targeting nicotine receptors after the drug licensed from Targacept failed in two remaining clinical trials, thinning out its pipeline further. While the news had been widely expected, since two previous Phase III studies also missed their targets, it hit shares in Targacept hard.
More
FAST FACTS
"Between 2001 and 2009, the number of people diagnosed with asthma grew by 4.3 million, according to the Centers for Disease Control and Prevention."
|
|
|
|
|
|
Mobile version
